Drug intelligence / Profile preview

VNBp-1

Development stage: Preclinical
Lead developer: Vitanova Biomedical
Modality: Small Molecules

Overview

**VNBp-1** is a light-activated, prostate specific membrane antigen (PSMA)-targeted investigational drug developed by Vitanova Biomedical as a first-line treatment for localized stage prostate cancer. It functions as an **apoptosis stimulant**, inducing programmed cell death in targeted cancer cells upon photoactivation, potentially offering a precise alternative to standard therapies like surgery or radiation with reduced side effects. Initially associated with The Vitanova Foundation, development has progressed to preclinical stages, supported by strategic partnerships such as with LiteCure Medical Lasers and grants from the National Science Foundation.[1][4][7][9]

Other names: VNBp 1VNBp1VNBp-1

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on VNBp-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VNBp-1.

Explore the full profile